Sara J. Buhrlage, Ph.D. - Publications

Affiliations: 
2015 Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States 
Area:
Chemical biology

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Koduri V, Duplaquet L, Lampson BL, Wang AC, Sabet AH, Ishoey M, Paulk J, Teng M, Harris IS, Endress JE, Liu X, Dasilva E, Paulo JA, Briggs KJ, Doench JG, ... ... Buhrlage SJ, et al. Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances. 7. PMID 33547076 DOI: 10.1126/sciadv.abd6263  0.52
2020 Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, ... ... Buhrlage SJ, et al. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. PMID 33275901 DOI: 10.1016/j.cell.2020.10.038  0.52
2020 Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical Research. 37: 167. PMID 32778962 DOI: 10.1007/s11095-020-02851-7  0.56
2020 Schauer NJ, Liu X, Magin RS, Doherty LM, Chan WC, Ficarro SB, Hu W, Roberts RM, Iacob RE, Stolte B, Giacomelli AO, Perera S, McKay K, Boswell SA, Weisberg EL, ... ... Buhrlage SJ, et al. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Scientific Reports. 10: 5324. PMID 32210275 DOI: 10.1038/s41598-020-62076-x  0.32
2020 Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD. Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. PMID 32144400 DOI: 10.1038/s41375-020-0782-4  0.56
2020 Yang J, Meng C, Weisberg E, Case A, Lamberto I, Magin RS, Adamia S, Wang J, Gray N, Liu S, Stone R, Sattler M, Buhrlage S, Griffin JD. Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer. PMID 32015510 DOI: 10.1038/s41416-020-0731-z  0.56
2020 Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Jimenez C, Chan GG, Hunter ZR, Palomba ML, Argyropoulos KV, Meid K, Keezer A, ... ... Buhrlage SJ, et al. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer Journal. 10: 12. PMID 32005797 DOI: 10.1038/s41408-020-0277-6  0.52
2020 Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Buhrlage SJ, Yang J, Liu X, Wang J, Gray N, Adamia S, Sattler M, Stone R, Griffin JD. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. Journal of Cellular and Molecular Medicine. PMID 31967735 DOI: 10.1111/jcmm.14927  0.56
2019 Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, et al. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British Journal of Haematology. PMID 31309543 DOI: 10.1111/bjh.16092  0.56
2019 Wang L, Ferrao R, Li Q, Hatcher JM, Choi HG, Buhrlage SJ, Gray NS, Wu H. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). The Journal of Biological Chemistry. PMID 30679311 DOI: 10.1074/jbc.RA118.005428  0.52
2019 Zheng Y, Ming P, Zhu C, Si Y, Xu S, Chen A, Wang J, Zhang B. Hepatitis B virus X protein-induced SH2 domain-containing 5(SH2D5) expression promotes hepatoma cell growth via an SH2D5-transketolase interaction. The Journal of Biological Chemistry. PMID 30659097 DOI: 10.1074/jbc.RA118.005739  0.32
2018 Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid KE, Gustine J, Dubeau T, Severns P, Castillo JJ, ... ... Buhrlage SJ, et al. BTKdrives ibrutinib resistance via ERK1/2, and protects BTKMYD88 mutated cells by a paracrine mechanism. Blood. PMID 29496671 DOI: 10.1182/blood-2017-10-811752  0.52
2017 Yao F, Liu Q, Zhang Z, Zhu X. RAFT Polymerization of Styrene and Maleimide in the Presence of Fluoroalcohol: Hydrogen Bonding Effects with Classical Alternating Copolymerization as Reference. Polymers. 9. PMID 30970767 DOI: 10.3390/polym9030089  0.32
2017 Wang L, Qiao Q, Ferrao R, Shen C, Hatcher JM, Buhrlage SJ, Gray NS, Wu H. Crystal structure of human IRAK1. Proceedings of the National Academy of Sciences of the United States of America. PMID 29208712 DOI: 10.1073/pnas.1714386114  0.52
2017 Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, ... ... Buhrlage SJ, et al. Inhibition of USP10 induces degradation of oncogenic FLT3. Nature Chemical Biology. PMID 28967922 DOI: 10.1038/nchembio.2486  0.56
2017 Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, et al. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 8: 52026-52044. PMID 28881711 DOI: 10.18632/oncotarget.19036  0.56
2017 Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, et al. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. PMID 28706155 DOI: 10.18632/oncotarget.19036  0.56
2017 Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW, Ligon KL, Hahn WC, ... ... Buhrlage SJ, et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-Oncology. PMID 28082416 DOI: 10.1093/neuonc/now261  0.52
2016 Ficarro SB, Browne CM, Card JD, Alexander WM, Zhang T, Park E, McNally R, Dhe-Paganon S, Seo HS, Lamberto I, Eck MJ, Buhrlage SJ, Gray NS, Marto JA. Leveraging Gas-Phase Fragmentation Pathways for Improved Identification and Selective Detection of Targets Modified by Covalent Probes. Analytical Chemistry. 88: 12248-12254. PMID 28193034 DOI: 10.1021/acs.analchem.6b03394  0.52
2016 Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, Gentles AJ, Martinez E, Zhu D, Chapman JR, Cortizas E, Shyam R, Chinichian S, Advani R, Tan L, ... ... Buhrlage SJ, et al. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood. PMID 27151888 DOI: 10.1182/blood-2016-02-696856  0.52
2016 Yang G, Buhrlage S, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. PMID 27143257 DOI: 10.1182/blood-2016-01-695098  0.4
2016 Liu X, Hunter ZR, Xu L, Chen J, Chen JG, Tsakmaklis N, Patterson CJ, Castillo JJ, Buhrlage S, Gray N, Treon SP, Yang G. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. British Journal of Haematology. PMID 27073043 DOI: 10.1111/bjh.14103  0.96
2016 Nishikawa JL, Boeszoermenyi A, Vale-Silva LA, Torelli R, Posteraro B, Sohn YJ, Ji F, Gelev V, Sanglard D, Sanguinetti M, Sadreyev RI, Mukherjee G, Bhyravabhotla J, Buhrlage SJ, Gray NS, et al. Inhibiting fungal multidrug resistance by disrupting an activator-Mediator interaction. Nature. PMID 26886795 DOI: 10.1038/nature16963  0.96
2015 Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, ... ... Buhrlage SJ, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. PMID 26165234 DOI: 10.1038/leu.2015.180  0.96
2015 Pery E, Sheehy A, Nebane NM, Brazier AJ, Misra V, Rajendran KS, Buhrlage SJ, Mankowski MK, Rasmussen L, White EL, Ptak RG, Gabuzda D. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. The Journal of Biological Chemistry. 290: 10504-17. PMID 25724652 DOI: 10.1074/jbc.M114.626903  0.96
2015 Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). Journal of Medicinal Chemistry. 58: 183-96. PMID 25075558 DOI: 10.1021/jm500480k  0.96
2014 Ritorto MS, Ewan R, Perez-Oliva AB, Knebel A, Buhrlage SJ, Wightman M, Kelly SM, Wood NT, Virdee S, Gray NS, Morrice NA, Alessi DR, Trost M. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nature Communications. 5: 4763. PMID 25159004 DOI: 10.1038/ncomms5763  0.96
2014 Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, ... Buhrlage SJ, et al. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. Acs Chemical Biology. 9: 1086-91. PMID 24556163 DOI: 10.1021/cb4008524  0.96
2014 Banerjee S, Buhrlage SJ, Huang HT, Deng X, Zhou W, Wang J, Traynor R, Prescott AR, Alessi DR, Gray NS. Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. The Biochemical Journal. 457: 215-25. PMID 24171924 DOI: 10.1042/BJ20131152  0.96
2013 Mistry H, Hsieh G, Buhrlage SJ, Huang M, Park E, Cuny GD, Galinsky I, Stone RM, Gray NS, D'Andrea AD, Parmar K. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Molecular Cancer Therapeutics. 12: 2651-62. PMID 24130053 DOI: 10.1158/1535-7163.MCT-13-0103-T  0.96
2013 Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 122: 1222-32. PMID 23836557 DOI: 10.1182/blood-2012-12-475111  0.96
2013 Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS. Developing irreversible inhibitors of the protein kinase cysteinome. Chemistry & Biology. 20: 146-59. PMID 23438744 DOI: 10.1016/j.chembiol.2012.12.006  0.96
2012 Deng X, Choi HG, Buhrlage SJ, Gray NS. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). Expert Opinion On Therapeutic Patents. 22: 1415-26. PMID 23126385 DOI: 10.1517/13543776.2012.729041  0.96
2012 Dockendorff C, Nagiec MM, Weïwer M, Buhrlage S, Ting A, Nag PP, Germain A, Kim HJ, Youngsaye W, Scherer C, Bennion M, Xue L, Stanton BZ, Lewis TA, Macpherson L, et al. Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies. Acs Medicinal Chemistry Letters. 3: 808-813. PMID 23074541 DOI: 10.1021/ml300172p  0.96
2011 Youngsaye W, Vincent B, Hartland CL, Morgan BJ, Buhrlage SJ, Johnston S, Bittker JA, MacPherson L, Dandapani S, Palmer M, Whitesell L, Lindquist S, Schreiber SL, Munoz B. Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates. Bioorganic & Medicinal Chemistry Letters. 21: 5502-5. PMID 21802942 DOI: 10.1016/j.bmcl.2011.06.105  0.96
2009 Buhrlage SJ, Bates CA, Rowe SP, Minter AR, Brennan BB, Majmudar CY, Wemmer DE, Al-Hashimi H, Mapp AK. Amphipathic small molecules mimic the binding mode and function of endogenous transcription factors. Acs Chemical Biology. 4: 335-44. PMID 19348463 DOI: 10.1021/cb900028j  0.96
2009 Buhrlage SJ, Chen B, Mapp AK. A flexible synthetic route to isoxazolidine β-proline analogs Tetrahedron. 65: 3305-3313. DOI: 10.1016/j.tet.2008.12.062  0.96
2007 Rowe SP, Casey RJ, Brennan BB, Buhrlage SJ, Mapp AK. Transcriptional up-regulation in cells mediated by a small molecule. Journal of the American Chemical Society. 129: 10654-5. PMID 17691790 DOI: 10.1021/ja0736865  0.96
2005 Buhrlage SJ, Brennan BB, Minter AR, Mapp AK. Stereochemical promiscuity in artificial transcriptional activators. Journal of the American Chemical Society. 127: 12456-7. PMID 16144370 DOI: 10.1021/ja0536567  0.96
Show low-probability matches.